Aktieanalys

Prolight Diagnostics: PoC troponin testing ready for next step - Emergers

Emergers Publicerad: 23 Feb 10:38

With proof-of-performance for its proprietary digital technique for detection of high-sensitive biomarkers even in whole blood, Prolight has taken significant steps forward in the past year. The share however, has experienced extended downwards pressure following the unit issue and subsequent compensation issue for the underwriters. Once the underwriters’ 150m shares have found their way to more sturdy investors, and the company continues to make progress with prototype development and IVDR certification towards launch in 2026, we expect the pressure to ease, and a revaluation that better reflects the long term prospects, where we find support for a fair value of SEK 1.1 – 1.2 per share.

Länk till analysen i sin helhet: https://www.emergers.se/prolight_b2/

Nyheter om Prolight Diagnostics

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!